Baseline tumor burden (median 111.16 mL; range 2.34–3475.45 mL) was not correlated with baseline ADAM12 and IL-6 concentrations (p = 0.29 and p = 0.28, respectively), indicating that the poor survival of patients with high baseline ADAM12 levels was not merely due to a higher tumor burden (see Figure S5 for representative images for primary tumor and metastases segmentation). The gene discussed is ADAM12; the disease is neoplasm.